Astrazeneca
Clinical trials sponsored by Astrazeneca, explained in plain language.
A global pharmaceutical company focused on oncology, cardiovascular, and respiratory diseases.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
One-shot CAR-T therapy takes on stem cell transplant for multiple myeloma
⭐️ CURE ⭐️ Not yet recruitingThis phase 3 trial tests whether a single infusion of AZD0120, a CAR-T cell therapy that targets two proteins on myeloma cells, can outperform the standard approach of high-dose chemotherapy followed by a stem cell transplant. The study enrolls adults newly diagnosed with multipl…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: ⭐️ CURE ⭐️
Last updated Aug 01, 2026 00:00 UTC
-
Can a new pill ease the burden of heart failure with preserved pumping?
Disease control Not yet recruitingThis phase 3 trial is testing whether an experimental drug called elecoglipron can reduce serious heart failure events, such as hospitalizations or urgent visits, in adults with heart failure with preserved or mildly reduced ejection fraction. Participants will receive either ele…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
A new pill aims to slow kidney failure and save lives
Disease control Not yet recruitingThis phase III trial is testing whether an experimental drug called elecoglipron can reduce the risk of serious kidney decline, kidney failure, or death in people with chronic kidney disease. About 7,000 adults with the condition, with or without type 2 diabetes, will receive eit…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a new antibody help lupus patients ditch steroids?
Disease control Not yet recruitingThis trial is testing whether anifrolumab, an experimental antibody, can help Chinese adults with moderate-to-severe systemic lupus erythematosus (SLE) achieve remission. Participants receive anifrolumab infusions over 52 weeks alongside standard care, with a focus on safely redu…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
A new strategy puts asthma guidelines to the test — could it cut flare-ups in half?
Disease control Not yet recruitingThis trial tests whether a structured care pathway — based on standard asthma guidelines — can improve disease management for adults with uncontrolled asthma who already use high-dose inhalers. Doctors and nurses at some clinics will receive extra training and tools to follow the…
Phase: NA • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug combo aims to stall advanced prostate cancer
Disease control Not yet recruitingThis study tests whether adding the experimental drug saruparib to standard hormone therapy can slow the growth of metastatic hormone-sensitive prostate cancer. It includes men whose cancer has not progressed after prior chemotherapy or a specific type of radiation therapy. Parti…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Continued anifrolumab treatment studied for lupus and related diseases
Disease control Not yet recruitingThis study offers continued access to anifrolumab (Saphnelo) for people with systemic lupus erythematosus, systemic sclerosis, or myopathies who completed a prior anifrolumab trial and are still benefiting from the drug. Participants receive the same treatment as before, while re…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Lupus drug anifrolumab tested as a simple shot
Disease control Not yet recruitingThis study tests anifrolumab, a drug for systemic lupus erythematosus (SLE), given either as a shot under the skin or through an IV. The goal is to see how the body processes the drug and check its safety. About 92 adults with lupus will take part.
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New pill aims to tame stubborn high blood pressure
Disease control Not yet recruitingThis study tests whether a new drug called baxdrostat can lower blood pressure in Chinese adults whose hypertension remains uncontrolled despite taking two or more blood pressure medications. Participants receive either baxdrostat or a placebo daily for 12 weeks, while continuing…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat myeloma
Disease control Not yet recruitingThis study tests a new treatment called AZD4045, which uses specially engineered immune cells (CAR-T cells) to target and kill multiple myeloma cells. The therapy is given alone or combined with other drugs (daratumumab and aldesleukin) in adults whose myeloma has returned or sto…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New lupus drug tested in kids for first time
Disease control Not yet recruitingThis study tests anifrolumab, a drug already used in adults with lupus, in children aged 5 to 17. The goal is to see how the drug moves through the body and if it is safe. Twenty-four children with moderate to severe lupus will receive the drug as a shot under the skin, while con…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New study monitors Real-World safety of asthma drug tezepelumab in korea
Disease control Not yet recruitingThis study observes 210 patients in South Korea who are prescribed Tezepelumab for severe asthma or chronic sinusitis with nasal polyps. Researchers will track side effects and how well the drug controls symptoms in everyday use. The goal is to confirm the drug's safety and effec…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New combo pill aims to supercharge cholesterol lowering
Disease control Not yet recruitingThis Phase 3 trial tests whether a new combination pill containing laroprovstat and rosuvastatin lowers LDL cholesterol better than rosuvastatin alone. About 200 adults with high cholesterol and a history of heart disease or high risk will take either the combo or a placebo plus …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New cholesterol combo pill aims to slash bad cholesterol without prior meds
Disease control Not yet recruitingThis study tests a new pill that combines two drugs (laroprovstat and rosuvastatin) to lower LDL or 'bad' cholesterol. About 600 adults with high cholesterol who have never taken cholesterol-lowering medication will receive either the combination, one of the drugs alone, or a pla…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo aims to slow kidney failure in High-Risk patients
Disease control Not yet recruitingThis phase 3 trial tests whether a combination of two drugs (balcinrenone and dapagliflozin) works better than dapagliflozin alone for people with advanced chronic kidney disease (stages 3b and 4). About 2,800 participants will take the combination or a placebo daily, alongside s…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
COPD drug breztri under Real-World watch in korea
Disease control Not yet recruitingThis study will follow 600 adults in Korea who have been prescribed Breztri for COPD, a long-term lung disease. Researchers want to see how safe the drug is in everyday use and whether it works as expected. Participants will take Breztri as their doctor prescribes, and the study …
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Roll-Over study offers continued benralizumab access for patients who benefit
Disease control Not yet recruitingThis study gives ongoing access to benralizumab (Fasenra) for people with asthma, eosinophilic granulomatosis with polyangiitis (EGPA), or hypereosinophilic syndrome (HES) who completed a prior benralizumab trial and still benefit from the drug. About 230 participants will receiv…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Eye scans could spot deadly heart disease before symptoms appear
Diagnosis Not yet recruitingThis study explores whether specialized eye imaging can identify people with a rare heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). Researchers will use machine learning to analyze eye scans from 500 adults—some with ATTR-CM and others with heart failure bu…
Sponsor: AstraZeneca • Aim: Diagnosis
Last updated Jul 10, 2026 00:00 UTC
-
Can immunotherapy be safely used in early lung cancer? a Real-World study investigates
Knowledge-focused Not yet recruitingThis observational study follows Indian adults with resectable non-small cell lung cancer who are prescribed durvalumab as part of their routine care. The goal is to monitor how often patients experience serious side effects, including severe adverse events and other complication…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Can dialysis change how a kidney drug works? a trial investigates
Knowledge-focused Not yet recruitingThis early-stage trial is testing whether hemodialysis—a treatment that filters waste from the blood when kidneys fail—changes how the body processes a combination drug called balcinrenone/dapagliflozin. The study will give a single dose of the drug to about 10 people with kidney…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Brazil tests lung cancer screening in smokers
Knowledge-focused Not yet recruitingThis study will screen 477 current or former smokers in Brazil for lung cancer using CT scans. It aims to see how often the scans give false alarms (false positives) in a region where lung infections are common. The goal is to improve screening accuracy and reduce unnecessary fol…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Blood tests could reveal hidden resistance in breast cancer
Knowledge-focused Not yet recruitingThis study observes people with a common type of advanced breast cancer (HR+/HER2-) who are already on standard hormone therapy. Researchers use simple blood tests to look for changes in the ESR1 gene, which can make the cancer stop responding to treatment. By tracking these muta…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
Experimental drug AZD4144 put through drug interaction test
Knowledge-focused Not yet recruitingThis study investigates how the experimental drug AZD4144 behaves in the body when taken alone and with itraconazole, a common antifungal. Healthy adults aged 18-55 with a BMI between 18 and 30 are eligible. The goal is to measure drug levels and clearance, helping to guide futur…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jul 08, 2026 00:00 UTC
-
AI could help detect lung cancer earlier in High-Risk smokers
Knowledge-focused Not yet recruitingThis study will enroll 1,500 current or former smokers aged 50-80 to see if an artificial intelligence (AI) model can help doctors better detect lung nodules and predict cancer spread. Participants will undergo CT scans, and the AI's results will be compared to standard radiologi…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Real-World study eyes drug combo for tough prostate cancer
Knowledge-focused Not yet recruitingThis study observes how well a combination of two drugs, olaparib and abiraterone, works as a first treatment for men with metastatic castration-resistant prostate cancer who have already tried other hormone therapies. Researchers will track how long patients stay on the treatmen…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
New study tracks safety of eplontersen in patients with liver transplants
Knowledge-focused Not yet recruitingThis observational study monitors the long-term safety of eplontersen, a treatment for transthyretin amyloidosis, in patients who have had a liver transplant or have severe liver impairment. Researchers will track side effects, lab changes, and serious health events in about 320 …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Massive study aims to standardize lung cancer testing across labs
Knowledge-focused Not yet recruitingThis study involves 3,400 people with advanced non-small cell lung cancer to see if a new test for a protein called TROP2 works consistently across different laboratories. The goal is to ensure that doctors can reliably use this test to guide treatment decisions. Participants pro…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Tiny study could unlock secrets of genetic heart failure
Knowledge-focused Not yet recruitingThis study follows 10 Chinese adults who have a specific gene mutation (BAG3) linked to dilated cardiomyopathy, a condition where the heart becomes enlarged and weak. Researchers will track changes in heart function, symptoms, and biomarkers over time to better understand how the…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New drug AZD4916 put to the test in healthy people first
Knowledge-focused Not yet recruitingThis early-stage study tests whether the experimental drug AZD4916 is safe and how it moves through the body in 160 healthy adults, including Japanese and Chinese volunteers. Participants receive either the drug or a placebo, and researchers monitor for side effects. This study d…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Massive review of 4,000 liver cancer patients aims to uncover regional trends
Knowledge-focused Not yet recruitingThis study will collect and analyze medical records from about 4,000 adults diagnosed with liver cancer (hepatocellular carcinoma) in Middle Eastern and North African countries between 2015 and 2023. Researchers want to understand what causes the cancer, how it is treated, and wh…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Tracing a cancer Drug's journey through the body
Knowledge-focused Not yet recruitingThis study tracks how the experimental drug AZD1390 moves through and leaves the body after a single dose. It involves about 8 adults with advanced solid tumors who are not currently on active cancer treatment. By using a tiny radioactive label, researchers can measure the drug i…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Can more screening catch lung cancer sooner? big study aims to find out
Knowledge-focused Not yet recruitingThis study looks at medical records of 3,000 adults with lung cancer to see if the stage at diagnosis is shifting to earlier, more curable stages. Researchers will track how often cancer is found through screening programs, chest X-rays, or heart scans. No new treatments or tests…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Kazakhstan cancer study to reveal Real-World treatment patterns
Knowledge-focused Not yet recruitingThis study will review medical records of about 240 adults in Kazakhstan with HER2-positive metastatic breast cancer to see how they were treated and how well they did. Researchers will look at treatments given in routine care (except one specific drug) and track outcomes like ho…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Why do lung cancer patients quit a key drug? new study seeks answers
Knowledge-focused Not yet recruitingThis study interviews about 85 patients with early-stage non-small cell lung cancer and 15 doctors to find out what makes it hard or easy to keep taking the drug osimertinib after surgery. The goal is to identify barriers like side effects, cost, or communication issues, and faci…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Brazilian study maps prostate cancer genes to improve treatment
Knowledge-focused Not yet recruitingThis study aims to learn about genetic changes in metastatic prostate cancer and how they affect patient outcomes. Researchers will collect and analyze tissue and blood samples from 100 adults in Brazil who are receiving standard palliative therapy. The goal is to better understa…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Lupus drug saphnelo under Real-World watch in women
Knowledge-focused Not yet recruitingThis study will look at how the lupus medication Saphnelo (anifrolumab) is being used in women aged 15 to 50 who could become pregnant. Researchers will track how many women use the drug each year and describe their health characteristics. The goal is to gather real-world informa…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC